Eagle Pharmaceuticals, Inc. (EGRX)
OTCMKTS
· Delayed Price · Currency is USD
0.650
+0.010 (1.56%)
Jan 17, 2025, 4:00 PM EST
Eagle Pharmaceuticals Revenue
Eagle Pharmaceuticals had revenue of $64.65M in the quarter ending June 30, 2023, a decrease of -12.80%. This brings the company's revenue in the last twelve months to $257.55M, down -5.38% year-over-year. In the year 2022, Eagle Pharmaceuticals had annual revenue of $316.61M with 84.56% growth.
Revenue (ttm)
257.55M
Revenue Growth
-5.38%
P/S Ratio
0.04
Revenue / Employee
1.92M
Employees
134
Market Cap
9.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 316.61M | 145.06M | 84.56% |
| Dec 31, 2021 | 171.55M | -16.26M | -8.66% |
| Dec 31, 2020 | 187.80M | -8.09M | -4.13% |
| Dec 31, 2019 | 195.89M | -17.42M | -8.17% |
| Dec 31, 2018 | 213.31M | -23.40M | -9.88% |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Sep 30, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
Eagle Pharmaceuticals News
- 2 months ago - Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration - GlobeNewsWire
- 2 months ago - Citigroup Inc's Strategic Reduction in Eagle Pharmaceuticals Inc Shares - GuruFocus
- 2 months ago - Eagle Pharmaceuticals names Christopher Krawtschuk as CFO - Seeking Alpha
- 2 months ago - Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - Benzinga
- 2 months ago - Nantahala Capital Management Reduces Stake in Eagle Pharmaceuticals - GuruFocus
- 3 months ago - INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders - Accesswire
- 3 months ago - Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares - GuruFocus
- 5 months ago - Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewsWire